Nucleolin targeting by a synthetic antagonist, N6L, inhibits Ang-2 secretion and participates in a program of EC loss-of-activation that increases the recruitment of perivascular cells and normalizes tumor vessels [196]. The gene discussed is NUCLEOLIN; the disease is neoplasm.